



Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

0T20 Rec'd PCT/PTO 29 AUG 2003

PCT/PTO

PTO/SB/21 (6-98)

Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/088,257

Filing Date

MARCH 15, 2002

First Named Inventor

FRANCOIS BERTELLI

Group Art Unit

Examiner Name

Attorney Docket Number

A0000179/2-01-EJB

### ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> --Copies of References cited in IDS
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> --Return postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> --Authorization debit/credit charge account 23-0455
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Eric J. Baude Reg. No. 47,413
Signature	
Date	8/25/03

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on this date: 8/25/03

Typed or printed name	Inja Cho
Signature	
Date	8/25/03

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313



1600  
1632

Please type a plus sign (+) inside this box → +

Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (6-98)

+

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/088,257
		Filing Date	March 15, 2002
		First Named Inventor	Francois Bertelli
		Group Art Unit	
		Examiner Name	
Total Number of Pages in This Submission	527	Attorney Docket Number	A0000179/2-66-MG

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i>	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
RECEIVED		
AUG 26 2002		
TECH CENTER 1600/2900		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Mehdi Ganjeizadeh	
Signature		
Date	8/15/02	

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 8/15/02			
Typed or printed name	Cindy Malocha		
Signature		Date	8/15/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

AUG 29 2003

JC27

U.S. PATENT &amp; TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

# FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** (\$ 180.00)

**Complaint Known**

Application Number	10/088,257
Filing Date	MARCH 15, 2002
First Named Inventor	FRANCOIS BERTELLI
Examiner Name	
Art Unit	
Attorney Docket No.	A0000179/2-01-EJB

**METHOD OF PAYMENT (check all that apply)**

Check  Credit card  Money Order  Other  None

**Deposit Account:**

Deposit Account Number  
23-0455

Warner-Lambert Company

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments

Charge any additional fee(s) during the pendency of this application

Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code (\$)	Fee Code (\$)		
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
<b>SUBTOTAL (1)</b>		(\$ 0.00)	

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims			
	-20** = 0	x 0	= 0
Multiple Dependent	- 3** = 0	x 0	= 0
			= 0

Large Entity	Small Entity	Fee Description
Fee Code (\$)	Fee Code (\$)	
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent
<b>SUBTOTAL (2)</b>		(\$ 0.00)

\*or number previously paid, if greater; For Reissues, see above

**3. ADDITIONAL FEES****Large Entity**

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180.00
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

**Other fee (specify)**

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)** (\$ 180.00)

**SUBMITTED BY**

(Complete if applicable)

Name (Print/Type)	Eric J. Baude	Registration No. (Attorney/Agent)	Telephone 734 622-2095
Signature	<i>Eric J. Baude</i>	Date	8/25/2003

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/090,827 ✓ 03/06/2002 ✓ Francois Bertelli A0000179-CI-66-MG 6882

7590 02/26/2003

Mehdi Ganjeizadeh  
Warner-Lambert Company  
2800 Plymouth Road  
Ann Arbor, MI 48105

MAR 04 2003

AA PATENT DEPT

L 512

EXAMINER  
WILDER, CYNTHIA B

ART UNIT PAPER NUMBER

1637

DATE MAILED: 02/26/2003

USSN: 10/088,257 Filed: 03/15/2002 Art Unit: 1614  
Docket: A00001792-01-EJB Inventor: Bertelli, et al.

Please find below and/or attached an Office communication concerning this application or proceeding.

Docketed

DATE 03-26-03  
FOR 1142-01-EJB  
BY: FGB CHECKED BY: \_\_\_\_\_

Docketed

DATE 03-26-03  
FOR 1142-01-EJB  
BY: FGB CHECKED BY: \_\_\_\_\_



Office Action Summary	Application No. <b>10/090,827</b>	Applicant(s) <b>BERTELLI et al.</b>
	Examiner <b>Cynthia B Wilder</b>	Art Unit <b>1637</b>

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1)  Responsive to communication(s) filed on Aug 23, 2002
- 2a)  This action is FINAL.      2b)  This action is non-final.
- 3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

#### Disposition of Claims

- 4)  Claim(s) 1-5 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5)  Claim(s) \_\_\_\_\_ is/are allowed.
- 6)  Claim(s) 1-5 is/are rejected.
- 7)  Claim(s) \_\_\_\_\_ is/are objected to.
- 8)  Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9)  The specification is objected to by the Examiner.
- 10)  The drawing(s) filed on \_\_\_\_\_ is/are a)  accepted or b)  objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11)  The proposed drawing correction filed on \_\_\_\_\_ is: a)  approved b)  disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12)  The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

- 13)  Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a)  All b)  Some\* c)  None of:
  1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\*See the attached detailed Office action for a list of the certified copies not received.

- 14)  Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  
a)  The translation of the foreign language provisional application has been received.
- 15)  Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

- 1)  Notice of References Cited (PTO-892)
- 2)  Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3)  Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6
- 4)  Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5)  Notice of Informal Patent Application (PTO-152)
- 6)  Other:

Art Unit: 1637

## DETAILED ACTION

### *Specification*

1. The specification is objected to because of the following informalities:
  - (a) The sequence identifier recited as "SEQ ID No" at pages 3, 4, 7, 16-18, 20, 21, 24, 26 and 29 and the sequence identifier recited as "SEQ ID N°" at page 6 is improper. It is suggested changing "SEQ ID No" and "SEQ ID N°" to "SEQ ID NO:" (See MPEP 2422.03).Appropriate correction is required.

### *Claim Rejections - 35 USC § 102(a)*

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the Applicant for a patent.

3. Claims 1, 3, 4, and 5 are rejected under 35 U.S.C. 102(a) as being anticipated by Brown et al. and Gee et al. (*Journal of Biological Chemistry*, Vol. 273, No. 39, pp 25458-465, September 25, 1998). Regarding claims 1, Brown and Gee teach a method for screening of a ligand which binds a cerebral cortical voltage-dependent calcium channel  $\alpha_2\delta-1$  subunit, the method comprising the steps of: contacting a secreted soluble recombinant calcium channel  $\alpha_2\delta-1$  subunit polypeptide with a ligand of interest and a labeled compound which binds the  $\alpha_2\delta-1$  subunit (page 25460, col. 1, lines 2-7, page 25462, col. 2, lines 6-13); and measuring the level of binding of the labeled compound to

Art Unit: 1637

the  $\alpha_2\delta-1$  subunit (Abstract and page 25461, subsection "Miscellaneous Methods" entire paragraph.

See also Fig. 2 and legend, page 26462.) Therefore, the reference of Brown and Gee meets all the claimed limitation of claim 1.

4. Regarding claims 3-5, Brown and Gee teach a method according to claim 1 and further teach a primary sequence of the porcine cerebral cortical voltage-dependent calcium channel  $\alpha_2\delta-1$  subunit cDNA (Figure 1, page 25459) comprising sequences that are identical to the sequences of SEQ ID NOS: 6-9. Brown and Gee additionally teach mutant forms of the cDNA sequence which resulted in secreted soluble recombinant calcium channel  $\alpha_2\delta-1$  subunits (see Figure 2, page 25462). Therefore, the reference of Brown and Gee meets all of the claimed limitations of claims 3-5.

*Claim Rejections - 35 USC § 103(a)*

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) a patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and

Art Unit: 1637

invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

7. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Brown and Gee as applied to claims 1, 3-5 above and further in view of Holland et al. (*Analytical Biochemistry*, November 1994). Regarding claim 2, Brown and Gee teach a method of screening of a ligand which bind the cerebral cortical voltage-dependent calcium channel  $\alpha_2\delta$ -1 subunit comprising the steps of contacting a secreted soluble recombinant calcium channel  $\alpha_2\delta$ -1 subunit polypeptide with a ligand of interest; and a labeled compound which binds the  $\alpha_2\delta$ -1 subunit; and measuring the level of binding of the labeled compound to the  $\alpha_2\delta$ -1 subunit.

The method of screening of Brown and Gee differs from that of the claim invention in that the reference does not expressly teach wherein the step of contacting and said binding is in a well of a flashplate.

Holland et al. teach a screening method of ligands using a flashplate assay wherein the contacting and binding is in the wells of a flashplate (see abstract). Holland et al. teach that the key feature of the flashplate binding assay is its simplicity. Holland et al. states that in essence, it comprises the addition of the radioligand and test compound, incubation and measurement and is convenient for screening compounds interacting at a receptor or quantitative receptor binding studies (page 517, last four lines bridging page 518, line 1). Holland further adds that no separation or washing steps are involved and this simplicity makes the assay more amenable to automation and

Art Unit: 1637

thus allows for a more robust assay. (page 517, col. 2, third paragraph; Discussion). Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have been motivated to have modified the ligand screening method of Brown and Gee by incorporating a flashplate assay as disclosed by Holland et al. One of ordinary skill in the art would have been motivated to do so for numerous advantages taught by Holland et al. that a flashplate assay is more simpler, more convenient and more robust for screening compounds interacting at a receptor or quantitative receptor binding studies and is more amendable to automation.

### *Conclusion*

8. No claims are allowed.
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Cynthia Wilder whose telephone number is (703) 305-1680. The examiner can normally be reached on Monday through Thursday from 9:30 am to 6:30 pm and on Friday from 9:30 am to 1:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached at (703) 308-1119. The official fax phone number for the Group is (703) 308-4242. The unofficial fax number is (703) 308-8724.


Any inquiry of a general nature or relating to the status of this application or proceeding should be directed the Group's receptionist whose telephone number is (703) 308-0196.

Application/Control Number: 10/090,827

Page 6

Art Unit: 1637

cbw  
February 24, 2003



Cynthia B. Wilder, Ph.D.  
Patent Examiner  
Art Unit 1637

**COPY**

## **FOREIGN PATENT DOCUMENTS**

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translatk	
						YES	NO
CW	93/04083	03/04/1993	WO			✓	

**OTHER DOCUMENTS** (*Including Author, Title, Date, Pertinent Pages, Etc.*)


GEE, N.S., ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, "THE NOVEL ANTICONVULSANT DRUG, GABAPENTIN (NEURONTIN), Binds TO THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL, 1996, VOL 271:10, PP. 5768-5776.

BROWN, J.P., ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, "CLONING AND DELETION MUTAGENESIS OF THE ALPHA2DELTA CALCIUM CHANNEL SUBUNIT FROM PORCINE CEREBRAL CORTEX", 1998, VOL. 273:39, PP. 25458-25465

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


**INFORMATION DISCLOSURE C. (Use several sheets if necessary)**

29 Aug 2003

 Docket Number (optional)  
**A0000179**

 Application Number  
**09/397,549**

 Applicant(s)  
**F. BERTELLI, ET AL.**

 Filing Date  
**16 SEPTEMBER 1999**

Group Art Unit

EXAMINER INITIAL	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
<i>CW</i>	<p>KOWALSKI, M.T., ET AL. BIOCHEMICAL SOCIETY TRANSACTIONS, "EFFECTS OF ANTI-CALCIUM CHANNEL A2-SUBUNIT ANTIBODIES ON CALCIUM FLUX AND 1,4-DIHYDROPYRIDINE BINDING" 1990, P. 890</p> <p>GURNETT, C.A., ET AL. THE J. OF BIOLOGICAL CHEMISTRY, "EXTRACELLULAR INTERACTION OF THE VOLTAGE-DEPENDENT CA<sub>2+</sub> CHANNEL ALPHA2 DELTA AND ALPHA1 SUBUNITS", 1997, 272:29 PP 18508-18512</p>
	<p>GURNETT, C.A., ET AL. NEURON, "DUAL FUNCTION OF THE VOLTAGE-DEPENDENT CA<sub>2+</sub> CHANNEL ALPHA2DELTA SUBUNIT IN CURRENT STIMULATION AND SUBUNIT INTERACTION" 1996, VOL. 16, PP 431-440</p> <p>FELIX, R., ET AL. J. OF NEUROSCIENCE, "DISSECTION OF FUNCTIONAL DOMAINS OF THE VOLTAGE-DEPENDENT CA<sub>2+</sub> CHANNEL ALPHA2DELTA SUBUNIT", 1997, VOL. 17:18, PP. 6884-6891</p>
	<p>FIELD, M.J., ET AL. BRITISH JOURNAL OF PHARMACOLOGY, "GABAPENTIN (NEURONTIN) AND S-(+)-3-ISOBUTYL GABA REPRESENT A NOVEL CLASS OF SELECTIVE ANTIHYPERALGESIC AGENTS", 1997, VOL. 121, PP. 1513-1522</p>
	<p>KLUGBAUER, N., ET AL. THE JOURNAL OF NEUROSCIENCE, "MOLECULAR DIVERSITY OF THE CALCIUM CHANNEL ALPHA2DELTA SUBUNIT", 1999, VOL. 19:2, PP. 684-691</p>
	<p>TOKUMARU, H., ET AL. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, "PURIFICATION OF THE CARDIAC 1,4-DIHYDROPYRIDINE RECEPTOR USING IMMUNOAFFINITY CHROMATOGRAPHY WITH A MONOClonAL ANTIBODY AGAINST THE ALPHA2DELTA SUBUNIT OF THE SKELETAL MUSCLE DIHYDROPYRIDINE RECEPTOR" 1992, VOL. 227, PP. 363-370.</p>
	<p>HILL, D.R., ET AL. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, "LOCALIZATION OF [<sup>3</sup>H]GABAPENTIN TO A NOVEL SITE IN RAT BRAIN: AUTORADIOGRAPHIC STUDIES", 1993, VOL. 244, PP. 303-309</p>
	<p>DISSANAYAKE, V.U.K., ET AL. BRITISH JOURNAL OF PHARMACOLOGY, "SPERMINE MODULATION OF SPECIFIC [<sup>3</sup>H]-GABAPENTIN BINDING TO THE DETERGENT-SOLUBILIZED PORCINE CEREBRAL CORTEX ALPHA2DELTA CALCIUM CHANNEL SUBUNIT" 1997, VOL. 120, PP. 833-840</p>
	<p>BRICKLEY, K., ET AL. FEBS LETTERS, "USE OF SITE-DIRECTED ANTIBODIES TO PROBE THE TOPOGRAPHY OF THE ALPHA2 SUBUNIT OF VOLTAGE-GATED CA<sub>2+</sub> CHANNELS", 1995, VOL. 364, PP. 129-133</p>
	<p>TAYLOR, C.P., ET AL. EPILEPSY RESEARCH, "POTENT AND STEREOSPECIFIC ANTICONVULSANT ACTIVITY OF 3-ISOBUTYL GABA RELATES TO IN VITRO BINDING AT A NOVEL SITE LABELED BY TRITIATED GABAPENTIN", 1993, VOL. 14, PP. 11-15</p>
	<p>THURLOW, R.J., ET AL. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, "[<sup>3</sup>H]GABAPENTIN MAY LABEL A SYSTEM-L-LIKE NEUTRAL AMINO ACID CARRIER IN BRAIN", 1993, VOL. 247, PP. 341-345</p>
	<p>SUMAN-CHAUHAN, N., ET AL. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, "CHARACTERISATION OF [<sup>3</sup>H]GABAPENTIN BINDING TO A NOVEL SITE IN RAT BRAIN: HOMOGENATE BINDING STUDIES", 1993, VOL. 244, PP. 293-301</p>
<i>V</i>	<p>ELLIS, S.B., ET AL. SCIENCE, "SEQUENCE AND EXPRESSION OF MRNAs ENCODING THE ALPHA1 AND ALPHA2 SUBUNIT OF A DHP-SENSITIVE CALCIUM CHANNEL", 1988, VOL. 241, PP. 1661-1664</p> <p>DEJONGH, K.S., THE JOURNAL OF BIOLOGICAL CHEMISTRY, "SUBUNITS OF PURIFIED CALCIUM CHANNELS", 1990, VOL. 265, PP. 14738-14741.</p>

EXAMINER

DATE CONSIDERED


2/21/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

References can be found in Parent application 09/397,549

INFORMATION DISCLOSURE C  
(Use several sheets if necessary)

AUG 29 2003



Docket Number (Optional)	A0000179~
Applicant(s)	F. BERTELLI, ET AL.
Filing Date	16 SEPTEMBER 1999
Group Art Unit	

Application Number	09/397,549
--------------------	------------

EXAMINER INITIAL	OTHER DOCUMENTS (Listing Author, Title, Date, Pertinent Pages, Etc.)
CW	JAY S.D., ET AL, THE JOURNAL OF BIOLOGICAL CHEMISTRY, "STRUCTURAL CHARACTERIZATION OF THE DIHYDROPYRIDINE-SENSITIVE CALCIUM CHANNEL ALPHA2-SUBUNIT AND THE ASSOCIATED DELTA PEPTIDES", 1991, VOL 266, PP. 3287-3293
CW	WISER, O., ET AL, FEBS LETTERS, "THE ALPHA2/DELTA SUBUNIT OF VOLTAGE SENSITIVE CA2+ CHANNELS IS A SINGLE TRANSMEMBRANE EXTRACELLULAR PROTEIN WHICH IS INVOLVED IN REGULATED SECRETION, 1996, VOL 379, PP. 15-20.
CG	BROWN, J.P., ET AL, REV. CONTEMP. PHARMACOTHER, "MECHANISMS OF ACTION OF GABAPENTIN", 1996, VOL 7, PP. 203-214
CW	BROWN, J.P., ET AL, ANALYTICAL BIOCHEMISTRY, "ISOLATION OF THE [3H]GABAPENTIN-BINDING PROTEIN/ALPHA2DELTA CA2+ CHANNEL SUBUNIT FROM PORCINE BRAIN: DEVELOPMENT OF A RADIOLIGAND BINDING ASSAY FOR ALPHA2DELTA SUBUNITS USING [3H]LEUCINE", 1998, VOL 255, PP. 236-243

EXAMINER

Cynthia Wilder

DATE CONSIDERED

2/21/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

References can be found in 09/397,549 SHEET 3 OF 3

FORM PTO-1449 U.S. DEPARTMENT OF  
(Rev. 2-32) TRADES & TRADEMARK PATENT AND  
TRADEMARK OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

ATTY. DOCKET NO.  
A0000179-C1-66-MG

SERIAL NO.  
10/090,827

APPLICANT  
FRANCOIS BERTELLI, ET AL.

COPY OF PAPERS  
ORIGINALLY FILED

FILING DATE  
March 6, 2002

GROUP  
1637

AUG 23 2002

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
CH	0 0 2 0 4 5 0	13.04.00	WO				x

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

CW	Holland et al., "A Nonseparation Microplate Receptor Binding Assay", <u>Analytical Biochemistry</u> , Vol. 222, 1994, pages 516-518

RECEIVED

AUG 26 2002

TECH CENTER 1600/2900

EXAMINER

*Cynthia Miller* DATE CONSIDERED *2/21/03*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

**Notice of References Cited**

O P E R A T I O N  
AUG 29 2003

U. S. Patent & Trademark Office

Application/Control No.  
**10/090,827**

Applicant(s)/Patent Under Reexam  
**BERTELLI et al.**

Examiner  
**Cynthia B Wilder**

Art Unit  
**1637**      Page 1 of 1

**U.S. PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY <sup>1</sup>	Name	Classification <sup>2</sup>
A				
B				
C				
D				
E				
F				
G				
H				
I				
J				
K				
L				
M				

**FOREIGN PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY <sup>1</sup>	Country	Name	Classification <sup>2</sup>
N					
O					
P					
Q					
R					
S					
T					

**NON-PATENT DOCUMENTS**

*	Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages		
x    u	Holland et al. A nonseparation microplate receptor binding Assay. Analytical Biochemistry, Vol. 222, pages 516-518.		
x    v	Brown and Gee. Cloning and Deletion Mutagenesis of the Alpha 2 beta calcium channel subunit from porcine cerebral cortex. Vol 273, No. 39, pages 25458-25465, September 1998.		
w			
x			

\* A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a).      <sup>1</sup>Dates in MM-YYYY format are publication dates.      <sup>2</sup>Classifications may be U.S. or foreign.